Matisse Pharmaceuticals secures € 1.9 million financing round led by Chemelot Ventures

november 17, 2016

Biotechnology company Matisse to proceed preclinical development followed by a phase I/II study for the development of M6229 for the treatment of severe sepsis and septic shock.

Matisse Pharmaceuticals, a biotechnology company focused on the development of pharmaceuticals to treat disorders that are associated with fulminant inflammation such as sepsis, announces a € 1.9 million financing round led by Chemelot Ventures. LBDF, management and other seed investors also participated in the round.

The new capital allows the company, located at Brightlands Chemelot Campus, to proceed and finalize its preclinical work and to continue its development work up to completion of a phase I/II study in men to reach the first molecular proof of concept. The program also entails a cGMP (current Good Manufacturing Practices) based manufacturing of the Investigational Medicinal Product (IMP), used for the phase I/II trial to investigate safety and dose ranging in septic patients.

The treatment of sepsis is still a serious medical challenge. Worldwide millions of people die each year from sepsis or septic shock. Sepsis is one of the most serious complications in the Intensive Care Units causing human suffering and high treatment costs.

The discovery of M6229 was made by researchers of the Cardiovascular Research Institute Maastricht (CARIM), part of the Maastricht Health Campus (MHC). Thanks to researchers Gerry Nicolaes and Chris Reutelingsperger, who combined several technologies available within MHC, initial elementary discoveries were translated into practical concepts for the treatment of sepsis within a relative short time frame.

”We are impressed by the preliminary preclinical data, showing a markedly increased survival of several animal species with bacterial blood infection. Given the smart concept of this breakthrough technology, we have high confidence that results can be repeated in a clinical setting. Such would increase survival for the many septic patients that now die in Intensive Care Units before standard of care antibiotic treatment becomes effective,” said Marcel Kloosterman, Director of Chemelot Ventures.

The consortium of investors includes lead investor Chemelot Ventures, LBDF and private seed investors, including a very significant investment of the management and inventors. We believe we have a solid financial basis now and investors who are strongly committed to make this development program a success,” said Bob Kool, CEO of Matisse Pharmaceuticals.

  overview news & events